Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
P/S ratio for Arcturus Therapeutics Holdings Inc. (ARCT)
P/S ratio as of 2023: 5.32
According to Arcturus Therapeutics Holdings Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.32. At the end of 2022 the company had a P/S ratio of 2.18.
P/S ratio history for Arcturus Therapeutics Holdings Inc. from 2011 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 5.32 |
| 2022 | 2.18 |
| 2021 | 78.81 |
| 2020 | 92.34 |
| 2019 | 6.31 |
| 2018 | 2.90 |
| 2017 | 1.90 |
| 2016 | 2.84 |
| 2015 | 22.14 |
| 2014 | 0.00 |
| 2013 | 0.00 |
| 2012 | 0.00 |
| 2011 | 0.00 |